Scorpius Holdings signed a contract to provide bioanalytical services for a publicly traded clinical-stage immuno-oncology company. This collaboration opens the door for further opportunities, as Scorpius expects to expand its services to include additional analytical work and future GMP manufacturing upon completion of this initial phase. This contract underscores Scorpius’ expertise in delivering critical bioanalytical and process development services, further establishing its role as a trusted partner in the biologics manufacturing space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCPX:
- Scorpius Holdings initiated with a Buy at ThinkEquity
- Scorpius Holdings commends passage of the BIOSECURE Act
- Scorpius Holdings selected for RRPV to accelerate countermeasure development
- Scorpius Holdings releases letter to shareholders from CEO
- Scorpius Holdings reports Q2 EPS ($26.98) vs. ($106.67) last year